Portfolio

Success you can see
Twilight Venture Partners has made investments in innovative life science companies, each with demonstrated valuation improvement.

Ambrx enables the biosynthesis of proteins with new physical, chemical and pharmacological properties using unnatural amino acid building blocks.

BioStorage Technologies develops and provides management, logistics and repository services for temperature-sensitive biological materials, manufactured product, and their associated data.

EndGenitor Technologies develops new therapeutics for cardiovascular and hematological disease using novel adult stem cells obtained from umbilical cord blood.

Endocyte is drug development company that is targeting a new generation of receptor-targeted therapeutics or "smart drugs" for the treatment of cancer and autoimmune diseases.

Given Imaging provides a first-line tool in the detection of abnormalities of the small bowel with a revolutionary PillCam ingestible camera.

Griffin Analytical Technologies (now a division of ICX Technologies) produces chemical detection systems that provide on-site confirmatory analysis by leveraging novel mass spectrometry technology.

Marcadia Biotech is a biopharmaceutical company focused on developing novel therapeutics that will greatly improve the daily life of people with diabetes and obesity.

NeoChord has developed a novel, minimally invasive surgical technology for mitral valve repair.

QuatRx Pharmaceuticals Company focuses on therapeutic compounds for the treatment of major endocrine, metabolic and cardiovascular diseases such as dyslipidemia, diabetes, and obesity.

Semafore is a small molecule drug discovery and development company that is targeting the PI3 kinase (PI3K) and PTEN cell-signaling pathway.

Suros Surgical Systems (now a division of Hologic, Inc.) is setting new industry standards for minimally invasive methods of tissue excision and biopsy in multiple surgical specialties.